Combination Chemotherapy in Treating Women With Stage I Breast Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by National Cancer Institute (NCI).
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
UNICANCER
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00055679
First received: March 6, 2003
Last updated: February 6, 2009
Last verified: December 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating early breast cancer.
PURPOSE: Randomized phase III trial to determine the effectiveness of different regimens of combination chemotherapy in treating women who have stage I breast cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Cancer |
Drug: cyclophosphamide Drug: epirubicin hydrochloride Drug: fluorouracil Drug: tamoxifen citrate Procedure: adjuvant therapy Radiation: radiation therapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase III Randomized Study Of Adjuvant Fluourouracil, Epirubicin And Cyclophosphamide, In Women With Stage I Breast Cancer |
Resource links provided by NLM:
Genetics Home Reference related topics:
breast cancer
Drug Information available for:
Cyclophosphamide
Fluorouracil
Tamoxifen
Tamoxifen citrate
Epirubicin hydrochloride
Epirubicin
U.S. FDA Resources
Further study details as provided by National Cancer Institute (NCI):
Primary Outcome Measures:
- Efficacy, in terms of 5-year survival [ Designated as safety issue: No ]
- Toxicity [ Designated as safety issue: Yes ]
- Length of survival with biological factors [ Designated as safety issue: No ]
- Biological factors significant for prognosis and prediction of survival [ Designated as safety issue: No ]
- Overall survival [ Designated as safety issue: No ]
| Estimated Enrollment: | 1512 |
| Study Start Date: | August 2002 |
OBJECTIVES:
- Compare the efficacy of 4 vs 6 courses of adjuvant fluorouracil, epirubicin, and cyclophosphamide, in terms of 5-year survival, in women with stage I breast cancer.
- Compare the toxicity of these regimens in these patients.
- Determine the correlation of length of survival with biological factors in patients treated with these regimens.
- Determine biological factors significant for prognosis and prediction of survival of patients treated with these regimens.
- Determine the overall survival of patients treated with these regimens.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive the same regimen as in arm I for up to 4 courses. After completion of chemotherapy, patients undergo radiotherapy 5 days a week for 6 weeks. Patients who are estrogen or progesterone receptor positive also receive oral tamoxifen daily for 5 years, beginning after completion of chemotherapy.
Patients are followed every 6 months for 5 years.
PROJECTED ACCRUAL: A total of 1,512 patients (756 per treatment arm) will be accrued for this study within 3 years.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed nonmetastatic, unilateral adenocarcinoma of the breast
- Stage I
- No clinically or radiologically suspicious metastases
- No positive sentinel lymph nodes by immunohistochemistry for tumors less than 2 cm
No clinically proven positive axillary lymph nodes
- Tumor cells found on immunohistochemistry only allowed
- No clinically or radiologically contralateral suspicious lesions
- No deeply adherent disease
- No cutaneous invasion
- No inflammatory disease
Complete surgical resection within the past 42 days
- At least 8 lymph nodes removed
- Tumor at least 1 cm with no residual disease
Presenting with at least 1 of the following factors of a poor prognosis:
- Tumor greater than 2 cm
- Hormone receptor negative tumor
- Grade II or III
- 35 years old or under
Hormone receptor status:
- Positive or negative
PATIENT CHARACTERISTICS:
Age
- 18 to 65
Sex
- Female
Menopausal status
- Not specified
Performance status
- WHO 0-1
Life expectancy
- Not specified
Hematopoietic
- WBC at least 2,000/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 1.25 times upper limit of normal (ULN)
- AST and ALT no greater than 1.25 times ULN
- Alkaline phosphatase no greater than 2.5 times ULN
- No chronic hepatitis B
- No active hepatitis C
Renal
- Creatinine no greater than 1.25 times ULN
Pulmonary
- FEV normal
Other
- Not pregnant or nursing
- HIV negative
- No prior breast cancer or other malignancy
- No familial, social, or geographical reason that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy
Endocrine therapy
- No prior anticancer hormone therapy
Radiotherapy
- No prior radiotherapy
Surgery
- See Disease Characteristics
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00055679
Hide Study Locations
Hide Study LocationsLocations
| France | |
| Clinique Claude Bernard | |
| Albi, France, 81000 | |
| Centre Paul Papin | |
| Angers, France, 49036 | |
| Centre Hospitalier d'Annecy | |
| Annecy, France, 74011 Cedex | |
| Centre Hospitalier Victor Dupouy | |
| Argenteuil, France, 95107 | |
| Centre Hospital General Robert Ballanger | |
| Aulnay Sous Bois, France, 93602 | |
| Centre Hospitalier d'Auxerre | |
| Auxerre, France, 89011 | |
| Institut Sainte Catherine | |
| Avignon, France, 84082 | |
| Centre Hospitalier de la Cote Basque | |
| Bayonne, France, 64100 | |
| C.H.G. Beauvais | |
| Beauvais, France, 60021 | |
| Centre Hospitalier General | |
| Belfort, France, 90000 | |
| Clinique Tivoli | |
| Bordeaux, France, F-33000 | |
| Institut Bergonie | |
| Bordeaux, France, 33076 | |
| Polyclinique Bordeaux Nord Aquitaine | |
| Boucher, France, 33300 | |
| Centre Hospitalier Docteur Duchenne | |
| Boulogne Sur Mer, France, 62200 | |
| Centre Hospitalier de Fleyriat | |
| Bourg En Bresse, France, 01012 | |
| Centre Hospitalier Jacques-Coeur | |
| Bourges, France, 18016 | |
| CHU Hopital A. Morvan | |
| Brest, France, 29609 | |
| Centre Hospitalier General | |
| Brive, France, 19101 | |
| Centre Regional Francois Baclesse | |
| Caen, France, 14076 | |
| Polyclinique Du Parc Centre Maurice Tubiana | |
| Caen, France, 14052 | |
| Centre Hospitalier Regional de Chambery | |
| Chambery, France, 73011 | |
| Clinique Prive Paul d'Egine | |
| Champigny-Sur-Marne, France, 94500 | |
| Centre Jean Perrin | |
| Clermont-Ferrand, France, 63011 | |
| Hopital Louis Pasteur | |
| Colmar, France, 68024 | |
| Clinique des Cedres | |
| Cornebarrieu, France, 31700 | |
| Centre de Lutte Contre le Cancer Georges-Francois Leclerc | |
| Dijon, France, 21079 | |
| Centre Hospitalier Draguignan | |
| Draguignan, France, 83300 | |
| CHU de Grenoble - Hopital de la Tronche | |
| Grenoble, France, 38043 | |
| Institut Prive de Cancerologie | |
| Grenoble, France, 38100 | |
| Centre Hospitalier Departemental | |
| La Roche Sur Yon, France, 85025 | |
| Centre Hospitalier de Lagny | |
| Lagny Sur Marne, France, 77405 | |
| Hopital Andre Mignot | |
| Le Chesnay, France, 78157 | |
| Centre Oscar Lambret | |
| Lille, France, 59020 | |
| Centre Hospitalier Bretagne Sud | |
| Lorient, France, 56322 | |
| Centre Leon Berard | |
| Lyon, France, 69373 | |
| Hopital de la Croix Rousse | |
| Lyon, France, 69317 | |
| Hopital Edouard Herriot | |
| Lyon, France, 69437 | |
| Hopital Hotel Dieu | |
| Lyon, France, 69288 | |
| Centre de Radiotherapie et Oncologie Saint-Faron | |
| Mareuil Les Meaux, France, 77100 | |
| Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes | |
| Marseille, France, 13273 | |
| Hopital Notre-Dame de Bon Secours | |
| Metz, France, 57038 | |
| Centre Hospitalier General Andre Boulloche | |
| Montbeliard, France, 25209 | |
| Intercommunal Hospital | |
| Montfermeil, France, 93370 | |
| Centre Azureen de Cancerologie | |
| Mougins, France, 06250 | |
| Centre Hospitalier de Mulhouse | |
| Mulhouse, France, 68051 | |
| Clinique D'Occitanie | |
| Muret, France, 31600 | |
| Centre Catherine de Sienne | |
| Nantes, France, 02 | |
| Centre Regional Rene Gauducheau | |
| Nantes-Saint-Herblain, France, 44805 | |
| Clinique Les Genets | |
| Narbonne, France, 11100 | |
| Clinique Hartmann | |
| Neuilly sur Seine, France, 92200 | |
| Hopital Saint Antoine | |
| Paris, France, 75571 | |
| Hopital Tenon | |
| Paris, France, 75970 | |
| C.H.G. De Pau | |
| Pau, France, 64046 Universite Cedex | |
| Polyclinique Francheville | |
| Perigueux, France, 24004 | |
| Clinique Saint - Pierre | |
| Perpignan, France | |
| Centre Hospitalier Lyon Sud | |
| Pierre Benite, France, 69495 | |
| CHU Poitiers | |
| Poitiers, France, 86021 | |
| Centre Hospitalier de Cornouaille | |
| Quimper, France, 29107 | |
| Centre Eugene Marquis | |
| Rennes, France, 35042 | |
| CHG Roanne | |
| Roanne, France, F-42300 | |
| Centre Hospitalier de Rodez | |
| Rodez, France, 12027 | |
| Clinique Armoricaine De Radiologie | |
| Saint Brieuc, France, F-22015 | |
| Centre Rene Huguenin | |
| Saint Cloud, France, 92211 | |
| Centre Paul Strauss | |
| Strasbourg, France, 67065 | |
| Centre Medico-Chirurgical Foch | |
| Suresnes, France, 92151 | |
| Polyclinique de L'Ormeau | |
| Tarbes, France, 65000 | |
| Institut Claudius Regaud | |
| Toulouse, France, 31052 | |
| Clinique Pasteur | |
| Toulouse, France, 31076 | |
| Clinique Du Parc | |
| Toulouse, France, 31078 | |
| Clinique du Chateau | |
| Toulouse, France, 31080 | |
| Hopital J. Ducuing | |
| Toulouse, France | |
| Centre Alexis Vautrin | |
| Vandoeuvre-les-Nancy, France, 54511 | |
Sponsors and Collaborators
UNICANCER
Investigators
| Study Chair: | Pierre Kerbrat, MD, PhD | Centre Eugene Marquis |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00055679 History of Changes |
| Other Study ID Numbers: | CDR0000270763, FRE-FNCLCC-PACS-05/0106, EU-20239 |
| Study First Received: | March 6, 2003 |
| Last Updated: | February 6, 2009 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
stage I breast cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Adjuvants, Immunologic Cyclophosphamide Fluorouracil Epirubicin Tamoxifen Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions Immunosuppressive Agents Antirheumatic Agents |
Therapeutic Uses Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Antibiotics, Antineoplastic Antimetabolites Antimetabolites, Antineoplastic Antineoplastic Agents, Hormonal Selective Estrogen Receptor Modulators Estrogen Receptor Modulators Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Bone Density Conservation Agents |
ClinicalTrials.gov processed this record on May 16, 2013